A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoCAIX in patients with CAIX-positive cancer
PH-CAIXGA-02/24
Phase 1 other active
Quick answer
A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoCAIX in patients with CAIX-positive cancer for Patients with suspected clear cell renal cell carcinoma (ccRCC) is a Phase 1 program (other) at Philogen S.p.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Philogen S.p.A.
- Indication
- Patients with suspected clear cell renal cell carcinoma (ccRCC)
- Phase
- Phase 1
- Modality
- other
- Status
- active